Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants

This multinational randomized trial assessed the efficacy of nirsevimab—a long-acting monoclonal antibody—for preventing hospitalizations due to RSV-associated lower respiratory tract infection in infants ≤12 months of age across France, Germany, and the United Kingdom. The study enrolled over 8000 infants and found that a single dose of nirsevimab reduced RSV-related hospitalizations by 83.2% compared to standard care. Very severe cases requiring supplemental oxygen were also significantly lower in the treatment group. Adverse events were minimal and consistent with expectations for monoclonal antibody use.

This multinational randomized trial assessed the efficacy of nirsevimab—a long-acting monoclonal antibody—for preventing hospitalizations due to RSV-associated lower respiratory tract infection in infants ≤12 months of age across France, Germany, and the United Kingdom. The study enrolled over 8000 infants and found that a single dose of nirsevimab reduced RSV-related hospitalizations by 83.2% compared to standard care. Very severe cases requiring supplemental oxygen were also significantly lower in the treatment group. Adverse events were minimal and consistent with expectations for monoclonal antibody use.